AUTHORS
Dany Nassar, MD, Elias Jabbour, MD2, Hannah Goulart, MD3, Nitin Jain, MD4, Fadi G. Haddad, MD5, Tapan Kadia I, MD6, Musa Yilmaz, MD7, Alessandra Ferrajoli III, MD8, Yesid Alvarado Valero, MD9, Naveen Pemmaraju, MD10, Jayastu Senapati, MBBS, MD, DM11, Farhad Ravandi, MD12, Rebecca Garris13, Min Zhao14, Guillermo Garcia-Manero, MD15, Nicholas Short, MD16, Hagop Kantarjian, MD17
AFFILIATIONS
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
3 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
4 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
5 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
6 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
7 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
10 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
11 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
12 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
13 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
14 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
15 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
16 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
17 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
ABSTRACT
Background
Frontline treatment with HCVAD followed by sequential blinatumomab (blina) produces high remission rates and excellent long-term survival in younger adults with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (B-ALL). Inotuzumab ozogamicin (InO), a CD22-directed antibody drug conjugate with established activity in relapsed/refractory B-ALL, was subsequently incorporated with the goal of deepening measurable residual disease (MRD) responses and reducing the risk of relapse. We report the updated 5-year outcomes of this phase II study to evaluate the long-term benefit of adding InO.
Methods
Adults aged 18-59 years with newly diagnosed Ph-negative B-cell ALL were enrolled in this single-arm phase II study. Patients (pts) were eligible after receiving no more than one prior cycle of chemotherapy. Treatment consisted of HCVAD alternating with high-dose methotrexate and cytarabine for up to 4 cycles, followed by 4 cycles of blina. Blina was introduced after 2 cycles of HCVAD in pts with high-risk biology or persistent measurable residual disease (MRD) detected by flow cytometry (FC). Pts with CD20 ≥1% received rituximab or ofatumumab. Beginning with patient #39, InO (0.3 mg/m2 on days 1 and 8) was added during two methotrexate/cytarabine and two blina cycles. Maintenance therapy included 15 cycles of POMP, with blina administered after every third cycle for a total of seven cycles. All pts received 12 doses of intrathecal chemotherapy and ursodiol prophylaxis.
Results
Seventy-five pts were treated: 38 without InO (cohort 1) and 37 with InO (cohort 2), with a median age in the overall cohort of 33 years (range, 18-59). Pts receiving InO were younger than those treated without InO (25 versus 37 years). Ph-like ALL was present in 16.2% versus 15.8%, TP53 alterations in 10.8% versus 27.0%, and low hypodiploid/near-triploid disease in 5.4% versus 15.8% in the InO and no-InO cohorts, respectively.
Of the 59 pts with active disease at enrollment, 84% achieved CR after induction, with similar rates in the InO and no-InO cohorts (89% versus 81%); all pts achieved CR at any time. MRD negativity by multiparameter flow cytometry (MFC) at any time was achieved in 95% of evaluable pts; these rates were 94% and 97% with and without InO; the corresponding MFC MRD-negativity rates at CR were 66% overall, 56% with InO and 76% without InO.
MRD-negativity by next generation sequencing (NGS) was achieved in 76% overall, in 17/22 (77%) with InO versus 10/18 (56%) without InO (P=0.19). In the subgroup with detectable NGS MRD following cycle 1, 6/7 pts (86%) receiving InO converted to NGS negativity before blina, compared with 3 of 8 pts (38%) treated without InO (P=0.12).
In Cohort 1, 14/38 pts (37%) underwent allogeneic stem cell transplant (SCT); 11 (78%) remain alive in remission, one died in CR, and two relapsed, both with high-risk cytomolecular features. Among the 24 pts who did not undergo SCT, 16 (67%) remain alive in CR, three died in CR, and five relapsed, four of whom subsequently died. In Cohort 2, 10 of 37 pts (27%) underwent SCT, and all remain alive in CR. Among the 27 pts who did not undergo SCT, 24 (89%) remain alive in CR and three relapsed.
After a median follow-up of 59 months overall, 83 months for cohort 1 and 52 months for cohort 2, the estimated 5-year OS rates was 89% overall, 79% without InO, and 100% with InO (P=0.0049). Corresponding 5-year EFS rates were 82%, 73%, and 91%, respectively (P=0.03). The 5-year cumulative incidence of relapse was lower with InO than without InO (8% versus 18%; P=0.177). In pts with high-risk disease, the 5-year OS rate was 100% with InO versus 71% without InO (P=0.051), while the 5-year EFS rate was 93% versus 71% (P=0.09). On multivariable analysis adjusting for age, high-risk disease, and SCT as a time-dependent covariate, InO remained independently associated with improved OS (HR, 0.07; 95% CI, 0.001–0.60; P=0.010) and showed a trend toward improved EFS (HR, 0.33; 95% CI, 0.08–1.05; P=0.061).
Conclusion
Extended follow-up of HCVAD blina +/ InO demonstrates excellent outcomes with the addition of InO further improving on the survival of pts with newly diagnosed Ph-negative ALL, including those with high-risk disease. A confirmatory randomized phase 2 trial is ongoing to confirm these findings.
DISCLOSURES
Dany Nassar, MD: No relevant conflicts of interest to declare.